Abstract
This chapter focuses on the role of ginseng in potential herb–drug interactions through inhibition of cytochrome P450 enzymes CYP3A4 and three polymorphisms of CYP2C9. Using commercial ginseng products and preparations made from authentic ginseng roots, CYP3A4 but not CYP2C9 inhibition correlated significantly with total ginsenoside content of the ginseng products tested. The inhibition of CYP2C9 was low for the three allelic forms and the profile of inhibition by product did not vary with the three polymorphisms tested. These in vitro results suggest that CYP3A4 inhibition, but not CYP2C9 inhibition, may warrant further study in a clinical setting.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sharma SK, Pandit MK (2009) A new species of Panax from Sikkim Himalaya, India. Syst Bot 34:434–438
Bahrke MS, Morgan WP (1994) Evaluation of the ergogenic properties of ginseng. Sports Med 18:229–248
Janetzki K, Morreale AP (1997) Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 54:692–693
Shader RI, Greenblatt DJ (1985) Phenelzine and the dream machine – ramblings and reflections. J Clin Psychopharmacol 5:65
Henderson GL, Harkey MR, Gershwin ME et al (1999) Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 65:209–214
He N, Edeki T (2004) The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11:206–212
Liu Y, Zhang JW, Li W et al (2006) Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. J Toxicol Sci 91:356–364
Hao M, Zhao Y, Chen P et al (2008) Structure–activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PloS One 3:e2697
Etheridge AS, Black SR, Patel PR et al (2007) An in vitro evaluation of cytochrome P450 inhibition and p-glycoprotein interaction with goldenseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731–741
Aithal GP, Day CP, Kesteven PJL et al (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719
Kirchheiner J, Brockmoller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1–16
Tam TW, Liu R, Arnason JT et al (2009) Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. J Ethnopharmacol 126:119–126
Yu R, Brown PN (2008) Single laboratory validation study for the determination of ginsenoside content in Panax ginseng C.A. Meyer and P. quinquefolius L. Raw Materials and finished Products by High Pressure Liquid Chromatography. 5th Annual NHP Research Conference Toronto Ontario, March 27–29, 2008
Acknowledgments
Extraction and HPLC-DAD methods were kindly validated and provided by Paula Brown (NHP Research Group, British Columbia Institute of Technology, Burnaby, Canada). This project was funded by the Ontario Ginseng Innovation and Research Centre (OGIRC).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Luu, A., Foster, B.C., McIntyre, K.L., Tam, T.W., Arnason, J.T. (2011). Pharmacogenetics in Potential Herb–Drug Interactions: Effects of Ginseng on CYP3A4 and CYP2C9 Allelic Variants. In: Gang, D. (eds) The Biological Activity of Phytochemicals. Recent Advances in Phytochemistry, vol 41. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7299-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7299-6_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6961-3
Online ISBN: 978-1-4419-7299-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)